Belzutifan: Primary Tx for Bilat Juxtapapillary Retinal Hemangioblastoma in VHL Patient

On this episode of the JVRD Author's Forum podcast, Dr. Nikhil Batra of the Dartmouth School of Medicine discusses "Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With von Hippel–Lindau Disease," published in the May/June 2025 issue of JVRD. Host Dr. Timothy Murray and Dr. Batra discuss how belzutifan, a HIF-2α inhibitor, was used off-label to successfully treat bilateral optic nerve hemangioblastomas in a patient with Von Hippel-Lindau Disease, resulting in significant tumor regression and visual improvement. Hear how this targeted therapy may represent a promising new direction in managing complex retinal tumors that are difficult to treat with traditional approaches. For more information, visit www.ASRS.org/JVRDForum. Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS), offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief of JVRD, as he discusses cutting-edge developments featured in JVRD with the lead authors, who share clinical pearls and explore their significance in advancing patient care.